Targeted therapy Vorasidenib offers hope for deadly brain tumors Neuroscience News
summary: A newly developed drug, Vorasidenib, has shown promising results in extending progression-free survival for patients with a subtype of glioma. The international study found that patients taking vorasidenib could go nearly 17 more months without their cancer getting worse, delaying the need for radiation and chemotherapy. The drug specifically targets IDH1/2 mutations in recurrent …
Targeted therapy Vorasidenib offers hope for deadly brain tumors Neuroscience News Read More »